AbbVie (ABBV) Non-Current Assets (2012 - 2026)

AbbVie has disclosed Non-Current Assets across 15 years of filings, most recently posting $102.9 billion for Q1 2026.

• In Q1 2026, Non-Current Assets fell 5.12% year-over-year to $102.9 billion; the TTM figure through Mar 2026 stood at $421.1 billion (down 4.69% YoY), while the FY2025 annual figure was $104.9 billion, down 4.27% from the prior year.
• Non-Current Assets retreated to $102.9 billion in Q1 2026, from $104.9 billion in the prior quarter.
• Over the last five years, Non-Current Assets for ABBV reached as high as $116.7 billion in Q1 2022 and fell as low as $101.7 billion in Q4 2023.
• The 5-year median for Non-Current Assets is $108.1 billion (2024), against an average of $108.5 billion.
• Annual changes were most pronounced in 2024 — Non-Current Assets grew 12.27% — and 2025, when it decreased 8.89%.
• A 5-year view of Non-Current Assets shows it stood at $110.3 billion in 2022, then declined by 7.82% to $101.7 billion in 2023, then advanced by 7.74% to $109.6 billion in 2024, then decreased by 4.27% to $104.9 billion in 2025, then dropped by 1.87% to $102.9 billion in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $102.9 billion, $104.9 billion, and $105.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.